|
1
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pui CH, Carroll WL, Meshinchi S and Arceci
RJ: Biology, risk stratification, and therapy of pediatric acute
leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Möricke A, Zimmermann M, Reiter A, Henze
G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G,
et al: Long-term results of five consecutive trials in childhood
acute lymphoblastic leukemia performed by the ALL-BFM study group
from 1981 to 2000. Leukemia. 24:265–284. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hunger SP, Lu X, Devidas M, Camitta BM,
Gaynon PS, Winick NJ, Reaman GH and Carroll WL: Improved survival
for children and adolescents with acute lymphoblastic leukemia
between 1990 and 2005: A report from the children's oncology group.
J Clin Oncol. 30:1663–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Conter V, Aricò M, Basso G, Biondi A,
Barisone E, Messina C, Parasole R, De Rossi G, Locatelli F, Pession
A, et al: Long-term results of the Italian Association of Pediatric
Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for
childhood acute lymphoblastic leukemia. Leukemia. 24:255–264. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pui CH, Campana D, Pei D, Bowman WP,
Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu
M, et al: Treating childhood acute lymphoblastic leukemia without
cranial irradiation. N Engl J Med. 360:2730–2741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhojwani D and Pui CH: Relapsed childhood
acute lymphoblastic leukaemia. Lancet Oncol. 14:e205–e217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Styczynski J and Drewa T: Leukemic stem
cells: From metabolic pathways and signaling to a new concept of
drug resistance targeting. Acta Biochim Pol. 54:717–726.
2007.PubMed/NCBI
|
|
9
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Makino S: The role of tumor stem-cells in
regrowth of the tumor following drastic applications. Acta Unio Int
Contra Cancrum. 15 Suppl 1:S196–S198. 1959.
|
|
11
|
Chávez-González A, Dorantes-Acosta E,
Moreno-Lorenzana D, Alvarado-Moreno A, Arriaga-Pizano L and Mayani
H: Expression of CD90, CD96, CD117, and CD123 on different
hematopoietic cell populations from pediatric patients with acute
myeloid leukemia. Arch Med Res. 45:343–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong D, Gupta R, Ancliff P, Atzberger A,
Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, et
al: Initiating and cancer-propagating cells in TEL-AML1-associated
childhood leukemia. Science. 319:336–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Toren A, Bielorai B, Jacob-Hirsch J,
Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky A,
Itskovitz-Eldor J, et al: CD133-positive hematopoietic stem cell
‘stemness’ genes contain many genes mutated or abnormally expressed
in leukemia. Stem cells. 23:1142–1153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wuchter C, Ratei R, Spahn G, Schoch C,
Harbott J, Schnittger S, Haferlach T, Creutzig U, Sperling C,
Karawajew L and Ludwig WD: Impact of CD133 (AC133) and CD90
expression analysis for acute leukemia immunophenotyping.
Haematologica. 86:154–161. 2001.PubMed/NCBI
|
|
15
|
Miraglia S, Godfrey W, Yin AH, Atkins K,
Warnke R, Holden JT, Bray RA, Waller EK and Buck DW: A novel
five-transmembrane hematopoietic stem cell antigen: Isolation,
characterization, and molecular cloning. Blood. 90:5013–5021.
1997.PubMed/NCBI
|
|
16
|
Horn PA, Tesch H, Staib P, Kube D, Diehl V
and Voliotis D: Expression of AC133, a novel hematopoietic
precursor antigen, on acute myeloid leukemia cells. Blood.
93:1435–1437. 1999.PubMed/NCBI
|
|
17
|
Morrison SJ and Scadden DT: The bone
marrow niche for haematopoietic stem cells. Nature. 505:327–334.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sheppard D: In vivo functions of
integrins: Lessons from null mutations in mice. Matrix Biol.
19:203–209. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Möhle R, Murea S, Kirsch M and Haas R:
Differential expression of L-selectin, VLA-4, and LFA-1 on
CD34+ progenitor cells from bone marrow and peripheral
blood during G-CSF-enhanced recovery. Exp Hematol. 23:1535–1542.
1995.PubMed/NCBI
|
|
20
|
Baer MR, Stewart CC, Lawrence D, Arthur
DC, Byrd JC, Davey FR, Schiffer CA and Bloomfield CD: Expression of
the neural cell adhesion molecule CD56 is associated with short
remission duration and survival in acute myeloid leukemia with
t(8;21)(q22;q22). Blood. 90:1643–1648. 1997.PubMed/NCBI
|
|
21
|
Gil ML, Vita N, Lebel-Binay S, Miloux B,
Chalon P, Kaghad M, Marchiol-Fournigault C, Conjeaud H, Caput D,
Ferrara P, et al: A member of the tetra spans transmembrane protein
superfamily is recognized by a monoclonal antibody raised against
an HLA class I-deficient, lymphokine-activated killer-susceptible,
B lymphocyte line. Cloning and preliminary functional studies. J
Immunol. 148:2826–2833. 1992.PubMed/NCBI
|
|
22
|
Miranti CK: Controlling cell surface
dynamics and signaling: How CD82/KAI1 suppresses metastasis. Cell
Signal. 21:196–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu W, Iiizumi-Gairani M, Okuda H,
Kobayashi A, Watabe M, Pai SK, Pandey PR, Xing F, Fukuda K, Modur
V, et al: KAI1 gene is engaged in NDRG1 gene-mediated metastasis
suppression through the ATF3-NFkappaB complex in human prostate
cancer. J Biol Chem. 286:18949–18959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu DH, Liu L, Chen LH and Ding YQ: KAI1
gene expression in colonic carcinoma and its clinical
significances. World J Gastroenterol. 10:2245–2249. 2004.PubMed/NCBI
|
|
25
|
Goncharuk VN, del-Rosario A, Kren L, Anwar
S, Sheehan CE, Carlson JA and Ross JS: Co-downregulation of PTEN,
KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in
non-small cell lung cancer. Ann Diagn Pathol. 8:6–16. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mooez S, Malik FA, Kayani MA, Rashid R,
Zahid A and Khan A: Expressional alterations and transcript
isoforms of metastasis suppressor genes (KAI1 and KiSS1) in breast
cancer patients. Asian Pac J Cancer Prev. 12:2785–2791.
2011.PubMed/NCBI
|
|
27
|
Burchert A, Notter M, Dietrich Menssen H,
Schwartz S, Knauf W, Neubauer A and Thiel E: CD82 (KAI1), a member
of the tetraspan family, is expressed on early haemopoietic
progenitor cells and up-regulated in distinct human leukaemias. Br
J Haematol. 107:494–504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nishioka C, Ikezoe T, Furihata M, Yang J,
Serada S, Naka T, Nobumoto A, Kataoka S, Tsuda M, Udaka K and
Yokoyama A: CD34+/CD38− acute myelogenous
leukemia cells aberrantly express CD82 which regulates adhesion and
survival of leukemia stem cells. Int J Cancer. 132:2006–2019. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vardiman JW: The World Health Organization
(WHO) classification of tumors of the hematopoietic and lymphoid
tissues: An overview with emphasis on the myeloid neoplasms. Chem
Biol Interact. 184:16–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Zou Y, Wang H, Chen X, Ruan M, Chen
Y, Yang W, Guo Y, Liu T, Zhang L, et al: Treatment outcome of
childhood standard-risk and median-risk acute lymphoblastic
leukemia with CCLG-2008 protocol. Zhonghua Er Ke Za Zhi.
52:449–454. 2014.(In Chinese). PubMed/NCBI
|
|
31
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dick JE: Stem cell concepts renew cancer
research. Blood. 112:4793–4807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guenova M and Balatzenko G: CD133-2
(AC141) expression analysis in acute leukemia immunophenotyping in
correlation to CD34 and P-glycoprotein. Hematology. 13:137–141.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bene MC, Castoldi G, Knapp W, Ludwig WD,
Matutes E, Orfao A and van't Veer MB: Proposals for the
immunological classification of acute leukemias. European Group for
the Immunological Characterization of Leukemias (EGIL). Leukemia.
9:1783–1786. 1995.PubMed/NCBI
|
|
35
|
Gallacher L, Murdoch B, Wu DM, Karanu FN,
Keeney M and Bhatia M: Isolation and characterization of human
CD34(−)Lin(−) and CD34(+)Lin(−) hematopoietic stem cells using cell
surface markers AC133 and CD7. Blood. 95:2813–2820. 2000.PubMed/NCBI
|
|
36
|
Yamamuro S, Okamoto Y, Sano E, Ochiai Y,
Ogino A, Ohta T, Hara H, Ueda T, Nakayama T, Yoshino A and Katayama
Y: Characterization of glioma stem-like cells from human
glioblastomas. Int J Oncol. 47:91–96. 2015.PubMed/NCBI
|
|
37
|
Welte Y, Davies C, Schäfer R and
Regenbrecht CR: Patient derived cell culture and isolation of
CD133+ putative cancer stem cells from melanoma. J Vis
Exp. e502002013.PubMed/NCBI
|
|
38
|
Bahnassy AA, Fawzy M, El-Wakil M, Zekri
AR, Abdel-Sayed A and Sheta M: Aberrant expression of cancer stem
cell markers (CD44, CD90 and CD133) contributes to disease
progression and reduced survival in hepatoblastoma patients: 4-year
survival data. Transl Res. 165:396–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li
JM, Yang T and Liu W: CD133 expression in osteosarcoma and
derivation of CD133+ cells. Mol Med Rep. 7:577–584.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang C, Xie J, Guo J, Manning HC, Gore JC
and Guo N: Evaluation of CD44 and CD133 as cancer stem cell markers
for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mak AB, Nixon AM and Moffat J: The mixed
lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133
transcription. Cancer Res. 72:1929–1934. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pellacani D, Packer RJ, Frame FM, Oldridge
EE, Berry PA, Labarthe MC, Stower MJ, Simms MS, Collins AT and
Maitland NJ: Regulation of the stem cell marker CD133 is
independent of promoter hypermethylation in human epithelial
differentiation and cancer. Mol Cancer. 10:942011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nishioka C, Ikezoe T, Yang J, Nobumoto A,
Kataoka S, Tsuda M, Udaka K and Yokoyama A: CD82 regulates
STAT5/IL-10 and supports survival of acute myelogenous leukemia
cells. Int J Cancer. 134:55–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nishioka C, Ikezoe T, Yang J and Yokoyama
A: Tetraspanin family member, CD82, regulates expression of EZH2
via inactivation of p38 MAPK signaling in leukemia cells. PLoS One.
10:e01250172015. View Article : Google Scholar : PubMed/NCBI
|
